RXi Pharmaceuticals Corp 4
4 · RXi Pharmaceuticals Corp · Filed Jun 9, 2017
Insider Transaction Report
Form 4
Eliseev Alexey
Chief Business Officer
Transactions
- Conversion
Common stock, $0.0001 par value
2017-06-09+332,499→ 1,150,312 total - Conversion
Series C Convertible Preferred Stock, $0.0001 par value
2017-06-09−332,499→ 0 total→ Common stock (332,499 underlying)
Footnotes (1)
- [F1]The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration.